Antibody engineering

Current Opinion in Immunology

Volumn 9, Issue 2, 1997, Pages 201-212

  Hayden, Martha S ^a   Gilliland, Lisa K ^b   Ledbetter, Jeffrey A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BISPECIFIC ANTIBODY; COMPLEMENTARY DNA;

BIOENGINEERING; DNA RECOMBINATION; GENETIC ENGINEERING; MOLECULAR CLONING; PHAGE DISPLAY; PROTEIN DOMAIN; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0030887996     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80136-7     Document Type: Article

References (127)

1. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 1991;Public Health Service, National Institutes Health, Washington, DC. [US Department of Health and Human Services publication no. 91-3242, 5th Edition].
2. Huston JS, Mudgett-Hunter M, Tai MS. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 203:1991;46-88.
3. Whitlow M, Filpula D. Single-chain Fv proteins and their fusion proteins. Methods: a companion to methods in enzymology. 2:1991;97-105.
4. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, Rollence ML, Wood JF, Schott ME, Milenic DE. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 6:1993;989-995.
5. Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 90:1993;6444-6448.
6. Alfthan K, Takkinen K, Sizmann D, Soderlund H, Teeri TT. Properties of a single-chain antibody containing different linker peptides. Protein Eng. 8:1995;725-731.
7. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotnyu J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 85:1988;5879-5883.
8. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning of Ig V domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA. 86:1989;3833-3837.
9. Bradbury A, Ruberti F, Werge T, Amati V, Di Luzio A, Gonfloni S, Hoogenboom H, Picciioli P, Biocca S, Cattaneo A. The cloning of hybridoma V regions for their ectopic expression in intracellular and intercellular immunization. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;295-353 Oxford University Press, Oxford, A nice summary of the cloning of hybridoma V regions and their use in creating novel molecules. The whole book is destined to become a classic reference for researchers in Ab engineering.
10. Gilliland LK, Norris NA, Marquardt H, Tsu TT, Hayden MS, Neubauer MG, Yelton DE, Mittler RS, Ledbetter JA. Rapid and reliable cloning of antibody V regions and generation of recombinant single chain antibody fragments. Tissue Antigens. 47:1996;1-20.
11. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al. Isolation of high-affinity antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
12. Marks JD. Human monoclonal antibodies from V-gene repertoires expressed on bacteriophage. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;53-69 Oxford University Press, Oxford, Another chapter from this excellent reference, including basic methods and protocols for generating and manipulating phage display libraries.
13. Glaser S, Kristensson K, Chilton T, Huse W. Engineering the antibody combining site by codon-based mutagenesis in a filamentous phage display system. Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;117-121 Oxford University Press, Oxford.
14. Barbas CF III, Burton DR. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 14:1996;230-234.
15. Duenas M, Borrebaeck CAK. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Biotechnology. 12:1994;999-1002.
16. De Kruif J, Terstappen L, Boel E, Logtenberg T. Rapid selection of cell subpopulation specific human monoclonal antibodies from a synthetic phage antibody library. of outstanding interest Proc Natl Acad Sci USA. 92:1995;3938-3942 Novel application of subtractive/sorted selection techniques for isolating new human anti-human binding specificities from heterogeneous Ab mixtures.
17. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. of outstanding interest Proc Natl Acad Sci USA. 93:1996;7843-7848 A recent paper which combines the power of Ab selection techniques with PCR to achieve single cell cloning of desired Ab cDNAs.
18. Winberg G, Grosmaire LS, Klussman K, Hayden MS, Fell HP, Ledbetter JA, Mittler RS. Surface expression of CD28 single chain Fv for costimulation by tumor cells. of special interest Immunol Rev. 153:1996;6-14 An extension of the intracellular expression of scFvs leading to cell surface expression thereby creating artificial adhesion receptors from scFv binding specificities.
19. Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res. 55:1995;3099-3104.
20. y antigen. Cancer Biol. 6:1995;289-295.
21. Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 14:1996;1239-1245.
22. Reiter Y, Pastan I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res. 2:1996;245-252.
23. Carter P, Ridgway JBB, Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J Hematotherapy. 4:1995;463-470.
24. Hayden MS, Linsley PS, Gayle MG, Bajorath J, Brady WA, Norris NA, Fell HP, Ledbetter JA, Gilliland LK. Single chain mono- and bispecific antibody derivatives with novel biological properties and anti-tumor activity from a COS cell transient expression system. Ther Immunol. 1:1994;3-15.
25. Kurucz I, Titus JA, Jost CR, Jacobus CM, Segal DM. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J Immunol. 154:1995;4576-4582.
26. Kranenborg MHGC, Boerman OC, Oosterwijk-Wakka JC, De Weijert MCA, Corstens FHM, Oosterwijk E. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res. 55:1995;5864-5867.
27. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA. 92:1995;7021-7025.
28. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van De Winkel JGJ, Lang N, Kalden JR. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcgammaRI and to HER-2/neu (MDX-210). J Hematotherapy. 4:1995;415-421.
29. Segal DM, Sconocchia G, Titus JA, Jost CR, Kurucz I. Alternative triggering molecules and single chain bispecific antibodies. J Hematotherapy. 4:1995;377-382.
30. Weiner LM, Clark JI, Davey M, Li WS, Garcia De Palazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcgammaRIII. Cancer Res. 55:1995;4586-4593.
31. 2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8:1995;301-314.
32. HER2 overexpressing tumor cells. Int J Cancer. 62:1995;319-324.
33. Hayden MS, Grosmaire LS, Norris NA, Gilliland LK, Winberg G, Tritschler D, Tsu TT, Linsley PS, Mittler RS, Senter PD, et al. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens. 48:1996;242-254.
34. 1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood. 87:1996;4390-4398.
35. 2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol Immunol. 33:1996;211-219.
36. Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD, Curiel DT. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. of special interest Gynecol Oncol. 59:1995;8-14 One of the first definitive reports of intracellular Ab fragments for potential use in tumor therapy.
37. Marasco WA, Haseltine WA, Chen S-Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA. 90:1993;7889-7893.
38. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single chain antibody. Proc Natl Acad Sci USA. 91:1994;5075-5079.
39. Werge TM, Baldari CT, Telford JL. Intracellular single chain Fv antibody inhibits Ras activity in T-cell antigen receptor stimulated Jurkat cells. FEBS Lett. 351:1994;393-396.
40. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Caberra G, Liu T, Kay M, Curiel DT. Targeted tumor killing via an intracellular antibody against erbB-2. of special interest J Clin Invest. 96:1995;2980-2989 This paper describes the construction and adenovirus-mediated expression of intracellular Abs against erbB-2 in tumor cells. It is a companion paper to [36].
41. Biocca S, Cataneo A. Intracellular immunization: antibody targeting to subcellular compartments. of special interest Trends Cell Biol. 5:1995;248-252 A nice review of subcellular targeting approaches and the sequence motifs necessary to achieve localization of expressed Ab fragments.
42. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology. 12:1994;396-399.
43. Hollenbaugh D, Douthwright J, McDonald V, Aruffo A. Cleavable CD40Ig fusion proteins and the binding to sgp39. J Immunol Methods. 188:1995;1-7.
44. Luo D, Mah N, Wishart D, Zhang Y, Jacobs F, Martin L. Construction and expression of bi-functional proteins of single-chain Fv with effector domains. J Biol Chem. 120:1996;229-232.
45. Trill JJ, Shatzman AR, Ganguly S. Production of monoclonal antibodies in COS and CHO cells. of special interest Curr Opin Biotechnol. 6:1995;553-560 An interesting review of selected mammalian expression techniques used for Ab production.
46. Kettleborough C, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 4:1991;773-783.
47. Chen S-Y, Khouri Y, Bagley J, Marasco WA. Combined intra- and extra-cellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA. 91:1994;5932-5936.
48. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blattler WA, Rees AR, Guild BC. Humanization of murine monoclonal antibodies through V domain resurfacing. Proc Natl Acad Sci USA. 91:1994;969-973.
49. Ames RS, Tornetta MA, Deen K, Jones CS, Swift AM, Ganguly S. Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobins. J Immunol Methods. 184:1995;177-186.
50. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high efficiency COS cell expression system. Proc Natl Acad Sci USA. 84:1987;8573-8577.
51. Linsley PS, Brady WA, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 173:1991;721-730.
52. Daugherty BV, Demartino JA, Law M-F, Kawka DW, Singer II, Mark GE. Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 19:1991;2471-2476.
53. Morrison SL, Coloma MJ, Espinoza D, Hastings A, Shin S-U, Wims LA, Wright A. Vectors and approaches for the eukaryotic expression of antibodies and antibody fusion proteins. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;267-291 Oxford University Press, Oxford, Another interesting chapter in this essential reference, outlining approaches and methods for eukaryotic expression of Ab derivatives.
54. Urlaub G, Kas E, Carothers AM, Chasin LA. Deletion of the diploid dihydrofolate reductase locus in cultured mammalian cells. Cell. 33:1983;405-412.
55. Kaufman RJ. Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol. 185:1990;537-566.
56. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology. 10:1992;169-175.
57. Bibila TA, Robinson DK. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol Prog. 11:1995;1-13.
58. McKinney KL, Dilwith R, Belfort G. Optimizing antibody production in batch hybridoma cell culture. J Biotechnol. 40:1995;31-48.
59. Guise AD, West SM, Chaudhuri JB. Protein folding in vivo and renaturation of recombinant proteins from inclusion bodies. Mol Biotechnol. 6:1996;53-64.
60. Ge L, Knappik A, Pack P, Freund C, Pluckthun A. Expressing antibodies in Escherichia coli. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;229-243 Oxford University Press, Oxford, A nice summary of Ab expression methods in E. coli as part of this comprehensive reference book.
61. Duenas M, Vazques J, Ayala M, Soderlind E, Ohlin M, Perez L, Borrebaeck CAK, Gavilondo JV. Intra and extracellular expression of an scFv antibody fragment in Ecoli: effect of bacterial strains and pathway engineering using GroES/L chaperonins. Biotechniques. 16:1994;476-483.
62. Huston JS, George AJT, Tai M-S, McCartney JE, Jin D, Segal DM, Keck P, Oppermann H. Single-chain Fv design and production by preparative folding. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;185-209 Oxford University Press, Oxford, A discussion and description of methods for refolding of Ab subunits produced in bacteria.
63. Rosenblum JS, Barbas CF III. Synthetic antibodies. of special interest Borrebaeck CAK. edn 2 Antibody engineering: a Practical Guide. 1995;89-105 Oxford University Press, Oxford, A discussion and description of methods for generating semisynthetic Ab libraries using phage display technology.
64. Hasemann CA, Capra JD. High-level production of a functional Ig heterodimer in a baculovirus expression system. Proc Natl Acad Sci USA. 87:1990;3942-3946.
65. Bei R, Schlom J, Kashmiri SVS. Baculovirus expression of a functional single-chain Ig and its IL-2 fusion protein. J Immunol Methods. 186:1995;245-255.
66. Kirkpatrick RB, Ganguly S, Angelichio M, Griego S, Shatzman A, Silverman C, Rosenberg M. Heavy chain dimers as well as complete antibodies are efficiently formed and secreted from Drosophila via a BiP mediated pathway. J Biol Chem. 270:1995;19800-19805.
67. Ma JK-C, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, Van Dolleweerd C, Mostov K, Lehner T. Generation and assembly of secretory antibodies in plants. of outstanding interest Science. 268:1995;716-719 An exciting development in successfully expressing intact, fully assembled secretory IgA molecules from transgenic tobacco plants, indicating that this may be an alternative for expressing complex, recombinant molecules.
68. Ma JK-C, Hein MB. Antibody production and engineering in plants. Collins GB, Shepherd RJ. Engineering Plants for Commercial Products and Applications. 1996;72-81 The New York Academy of Sciences, New York.
69. Tavladoraki P, Franconi R, Bradbury A, Cattaneo A, Benvenuto E. The expression of 'single chain' antibodies in transgenic plants. of special interest Borrebaeck CAK. edn 2 Antibody Engineering: a Practical Guide. 1995;363-367 Oxford University Press, Oxford, Again part of an excellent reference, this chapter summarizes approaches for Ab expression from transgenic plants.
70. Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. of special interest Trends Biotechnol. 13:1995;306-310 Excellent review of an emerging field in applied Ab engineering.
71. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy. 1:1994;332-337.
72. Deshane J, Grim J, Loechel S, Siegal GP, Pike J, Alvarez RD, Curiel DT. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3:1996;89-98.
73. Joliffe LK. Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int Rev Immunol. 10:1993;241-250.
74. Hurle MR, Gross M. Protein engineering techniques for antibody humanization. Curr Opin Biotechnol. 5:1994;428-433.
75. Gorman SD, Clark MR, Routledge EG, Cobbold SP, Waldmann H. Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci USA. 88:1991;4181-4185.
76. Tempest PR, White P, Buttle M, Carr FJ, Harris WJ. Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int J Biol Macromol. 17:1995;37-42.
77. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327.
78. Foote J, Winter G. Antibody framework residues determining the conformation of the hypervariable loops. J Mol Biol. 224:1992;487-499.
79. Benhar I, Padlan EA, Jung SH, Lee B, Pastan I. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3 (Fv)-PE38. Proc Natl Acad Sci USA. 91:1994;12051-12055.
80. Rosok MJ, Yelton DE, Harris LJ, Bajorath J, Hellstrom K-E, Hellstrom I, Cruz GA, Kristensson K, Lin H, Huse WD, Glaser SM. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. of special interest J Biol Chem. 271:1996;22611-22618 First report of a rapid and efficient method for humanizing murine Abs.
81. Waterhouse P, Griffiths AD, Johnson KS, Winter G. Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. Nucleic Acids Res. 21:1993;2265-2266.
82. O'Neil KT, Hoess RH. Phage display: protein engineering by directed evolution. Curr Opin Struct Biol. 5:1995;443-449.
83. Soderlind E, Vergeles M, Borrebaeck CAK. Domain libraries: synthetic diversity for de novo design of antibody V-regions. Gene. 160:1995;269-272.
84. De Kruif J, Boel E, Logtenberg T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol. 248:1995;97-105.
85. Geoffroy F, Sodoyer R, Aujame L. A new phage display system to construct multicombinatorial libraries of very large antibody repertoires. Gene. 151:1994;109-113.
86. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:1994;692-698.
87. Marks JD, Griffiths AD, Malmquist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high-affinity human antibodies by chain shuffling. Biotechnology. 10:1992;779-783.
88. Smith JW, Hu D, Satterthwait A, Pinz-Sweeney S, Barbas CF III. Building synthetic antibodies as adhesive ligands for integrins. J Biol Chem. 269:1994;32788-32795.
89. Yelton DE, Rosok MJ, Cruz G, Cosand WL, Bajorath J, Hellstrom I, Hellstrom KE, Huse WD, Glaser SM. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol. 155:1995;1994-2004.
90. Barbas CF III, Hu D, Dunlop H, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA. 91:1994;3809-3813.
91. Yang W-P, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF III. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 254:1995;392-403.
92. Low NM, Holliger P, Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol. 260:1996;359-368.
93. Barbas CF III. Synthetic human antibodies. Nat Med. 1:1995;837-839.
94. Meulemans EV, Slobbe R, Wasterval P, Ramaekers FCS, Van Eys GJJM. Selection of phage displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody. J Mol Biol. 244:1994;353-360.
95. Ohlin M, Borrebaeck CAK. Characteristics of human antibody repertoires following active immune responses in vivo. Mol Immunol. 33:1996;583-592.
96. Green LL, Hardy MH, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. 17:1994;13-21.
97. Tuaillon N, Taylor LD, Lonberg N, Tucker PW, Capra JD. Human Ig heavy-chain minilocus recombination in transgenic mice: gene-segment use μ and γ transcripts. Proc Natl Acad Sci USA. 90:1993;3720-3724.
98. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo C-C, Mashayekh R, Wymore K, Macabe JG. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 368:1994;856-859.
99. Taylor LD, Carmack CE, Schramm SR, Mashayekh KM, Higgins KM, Duo C-C, Woodhouse CS, Kay RM, Lonberg N. A transgenic mouse that expresses a diversity of human sequence heavy and light chain Igs. Nucleic Acids Res. 20:1992;6287-6295.
100. Wagner SD, Popov AV, Davies SL, Xian J, Neuberger MS, Bruggemann M. The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human Ig gene miniloci. Eur J Immunol. 42:1994;2672-2681.
101. Lonberg N, Huszar D. Human antibodies from transgenic mice. Int Rev Immunol. 13:1995;65-93.
102. Jakobovits A. Production of fully human antibodies by transgenic mice. of special interest Curr Opin Biotechnol. 6:1995;561-566 An excellent review of important developments permitting the construction of human Ig-expressing transgenic mice.
103. Jakobovits A, Moore AL, Green LL, Vergara GJ, Maynard-Currie CE, Austin HA, Klapholz S. Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature. 362:1993;255-258.
104. Bruggemann M, Neuberger MS. Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today. 17:1996;391-397.
105. Mendez MJ, Abderrahim H, Noguchi M, David NE, Hardy MH, Green LL, Tsuda H, Yoast S, Maynard-Currie CE, Garza D. Analysis of the structural integrity of YACs comprising human Ig genes in yeast and in embryonic stem cells. Genomics. 26:1995;294-307.
106. Bruggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA, Neuberger MS. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA. 86:1989;6709-6713.
107. Taylor LD, Carmack CE, Huszar D, Higgins KM, Mashayekh R, Sequar G, Schramm SR, Kuo C-C, O'Donnel SL, Kay RM. Human Ig transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int Immunol. 6:1994;579-591.
108. Duenas M, Chin L-T, Malmborg A-C, Casalvilla R, Ohlin M, Borrebaeck CAK. In vitro immunization of naive human B cells yields high-affinity Ig G antibodies as illustrated by phage display. of outstanding interest Immunology. 89:1996;1-7 Interesting report of a successful approach to achieving affinity maturation from human B cells stimulated in vitro.
109. Chen S-Y, Khouri ZC. Design of genetic immunotoxins to eliminate toxin immunogenicity. of special interest Gene Ther. 2:1995;116-123 This paper describes a very clever use of fusion protein technology to delay immunotoxin expression until after delivery to the target cell.
110. Chen S-Y, Marasco WA. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol. 23:1996;148-153.
111. Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys. 93:1961;460-462.
112. Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 121:1986;210-228.
113. Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, De Leij L. The role of apoptosis in bispecific antibody mediated T cell cytotoxicity. Br J Cancer. 73:1996;721-727.
114. H3 domains for heavy chain heterodimerization. Protein Eng. 9:1996;617-621.
115. of special interest McGuinness BT, Walter G, Fitzgerald K, Schuler P, Mahoney W, Duncan AR, Hoogenboom HR. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nat Biotechnol. 14:1996;1149-1153 A potentially powerful technique for creating and testing libraries of bispecific diabody repertoires if library stability can be demonstrated.
116. Pack P, Pluckthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 31:1992;1579-1584.
117. Pack P, Muller K, Zahn R, Pluckthun A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol. 246:1995;28-34.
118. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol. 148:1992;1547-1553.
119. of special interest De Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem. 271:1996;7630-7634 Describes the use of fos-jun leucine zipper dimerization domains to achieve assembly of bispecific scFv molecules.
120. Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Pluckthun A, Pack P. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol. 157:1996;2989-2997.
121. Fagerstam L. A non-label technology for real time biospecific interaction analysis. Tech Prot Chem. 2:1991;65-71.
122. Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 198:1991;268-277.
123. Kramer A, Vakalopoulou E, Schleuning W-D, Schneider-Mergener J. A general route to fingerprint analyses of peptide-antibody interactions using a clustered amino acid peptide library: comparison with a phage display library. Mol Immunol. 32:1995;459-465.
124. Bonnycastle LC, Mehroke JS, Rashed M, Gong X, Scott JK. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol. 258:1996;747-762.
125. Peterson NC, Greene MI. Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Ther Immunol. 1:1994;289-295.
126. Levi M, Sallberg M, Ruden U, Herlyn D, Maruyama H, Wigzell H, Marks J, Wahren B. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA. 90:1993;4374-4378.
127. of outstanding interest Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-463 A particularly elegant and complete presentation of results from a search for peptide mimetics of the protein hormone erythropoietin.